Viewing Study NCT05057494


Ignite Creation Date: 2025-12-25 @ 1:31 AM
Ignite Modification Date: 2025-12-28 @ 12:06 AM
Study NCT ID: NCT05057494
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-17
First Post: 2021-09-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module